Stay updated on IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial
Sign up to get notified when there's something new on the IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial page.

Latest updates to the IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page revision tag was updated from v3.5.2 to v3.5.3, indicating a new published version of the content. No substantive content changes are indicated by this update.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision number updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check37 days agoChange Detected- Added the term 'Squamous cell carcinoma of the head and neck' to the study's conditions / MeSH terms to reflect the applicable disease category.SummaryDifference0.1%

- Check44 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0 across the site. No changes to study content or functionality are indicated.SummaryDifference0.1%

- Check58 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check87 days agoChange DetectedThe page was updated to Revision v3.4.2 and the government funding lapse notice was removed; no core trial information, eligibility criteria, or patient-facing content were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial page.